Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

XTL 6865

Other · developed by XTL Biopharmaceuticals

Phase 1 Most advanced trial (none active)
XTLB Developer
1 Registered trials

What is XTL 6865?

XTL 6865 is an investigational drug studied in Hepatitis C.

At a glance

Drug type
Other
Therapy area
Infectious disease
Developer
XTL Biopharmaceuticals (XTLB)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT00300807 Phase 1 Hepatitis C Unknown XTLB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hepatitis C

More from XTL Biopharmaceuticals

Bicifadine Phase 2

Follow XTLB, the company behind XTL 6865

See XTLB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

XTLB catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.